Although AbbVie saw sales rise to $8.31 billion in the fourth quarter, the increase was still a blow to the company’s stock because it came below analysts’ estimate of $8.38 billion for the quarter. In the fourth quarter of 2017, AbbVie had sales of $7.74 billion.
Revenue growth in the fourth quarter was attributed to a 50 percent increase in the company’s global hematologic oncology profile, according to the report.
AbbVie’s stock fell 6 percent Jan. 25 on news of the missed estimate in the fourth quarter.
More articles on pharmacy:
Cancer therapy prices prevent access to treatment, WHO says
Despite controversies, J&J ranks among Fortune’s most-admired companies
Bristol-Myers swings to $1.2B profit in Q4
